Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sunkyu Kim

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
ACS Medicinal Chemistry Letters|November 17, 2022
Discovery of 5,7-Dihydro-6<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-6-ones as Highly Selective CDK2 InhibitorsAlexander Sokolsky, Sarah Winterton, Keith Kennedy, et al.
Molecular Cancer Therapeutics|July 17, 2014
Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivoYi-Xiang Zhang, Ewa Sicinska, Jeffrey T Czaplinski, et al.
Scientific Data|June 28, 2020
Building a PubMed knowledge graphJian Xu, Sunkyu Kim, Min Song, et al.
JCO Clinical Cancer Informatics|August 16, 2024
Deep-Transfer-Learning-Based Natural Language Processing of Serial Free-Text Computed Tomography Reports for Predicting Survival of Patients With Pancreatic CancerSunkyu Kim, Seung-Seob Kim, Eejung Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2017
Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic LeukemiaYana Pikman, Gabriela Alexe, Giovanni Roti, et al.
Oncotarget|November 17, 2018
The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer modelsSunkyu Kim, Ralph Tiedt, Alice Loo, et al.
Oncotarget|April 16, 2020
Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer modelsSunkyu Kim, Ralph Tiedt, Alice Loo, et al.
The Journal of Biological Chemistry|October 10, 2003
Proteomics-based target identification: bengamides as a new class of methionine aminopeptidase inhibitorsHarry Towbin, Kenneth W Bair, James A DeCaprio, et al.
Journal of Medicinal Chemistry|September 20, 2025
Discovery of Fluoroalkenes as Dual Inhibitors of Diacylglycerol Kinases Alpha and Zeta (DGKα/ζ)Ming Xiang, Shicheng Shi, Shaoqun Qian, et al.
Small (Weinheim an Der Bergstrasse, Germany)|December 28, 2023
Unusual Raman Enhancement Effect of Ultrathin Copper SulfideGwangwoo Kim, Du Won Jeong, Geonhee Lee, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
ACS Medicinal Chemistry Letters|November 17, 2022
Discovery of 5,7-Dihydro-6<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-6-ones as Highly Selective CDK2 InhibitorsAlexander Sokolsky, Sarah Winterton, Keith Kennedy, et al.
Molecular Cancer Therapeutics|July 17, 2014
Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivoYi-Xiang Zhang, Ewa Sicinska, Jeffrey T Czaplinski, et al.
Scientific Data|June 28, 2020
Building a PubMed knowledge graphJian Xu, Sunkyu Kim, Min Song, et al.
JCO Clinical Cancer Informatics|August 16, 2024
Deep-Transfer-Learning-Based Natural Language Processing of Serial Free-Text Computed Tomography Reports for Predicting Survival of Patients With Pancreatic CancerSunkyu Kim, Seung-Seob Kim, Eejung Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2017
Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic LeukemiaYana Pikman, Gabriela Alexe, Giovanni Roti, et al.
Oncotarget|November 17, 2018
The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer modelsSunkyu Kim, Ralph Tiedt, Alice Loo, et al.
Oncotarget|April 16, 2020
Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer modelsSunkyu Kim, Ralph Tiedt, Alice Loo, et al.
The Journal of Biological Chemistry|October 10, 2003
Proteomics-based target identification: bengamides as a new class of methionine aminopeptidase inhibitorsHarry Towbin, Kenneth W Bair, James A DeCaprio, et al.
Journal of Medicinal Chemistry|September 20, 2025
Discovery of Fluoroalkenes as Dual Inhibitors of Diacylglycerol Kinases Alpha and Zeta (DGKα/ζ)Ming Xiang, Shicheng Shi, Shaoqun Qian, et al.
Small (Weinheim an Der Bergstrasse, Germany)|December 28, 2023
Unusual Raman Enhancement Effect of Ultrathin Copper SulfideGwangwoo Kim, Du Won Jeong, Geonhee Lee, et al.
Pageof 7